piracetam has been researched along with Brain Neoplasms in 68 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a case series analysis to evaluate the effects of levetiracetam (LEV) monotherapy on seizures, adverse events, cognitive functioning and quality of life (QoL) in patients with brain tumor-related epilepsy (BTRE)." | 9.15 | Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. ( Dinapoli, L; Fabi, A; Maschio, M; Muti, P; Pace, A; Sperati, F; Vidiri, A, 2011) |
| "Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures." | 9.14 | Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. ( Barbaro, N; Burt, M; Chakalian, L; Chang, E; Chang, S; Lamborn, KR; Lim, DA; McDermott, MW; Tarapore, P, 2009) |
| "To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection." | 8.86 | A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. ( Finch, CK; Michael, LM; Sills, AK; Usery, JB, 2010) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 7.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| "LEV may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy." | 7.81 | Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. ( Han, JH; Joo, JD; Kim, CY; Kim, IA; Kim, T; Kim, YH; Kim, YJ; Yun, CH, 2015) |
| "We report a case of neutropenia related to the use of levetiracetam at first exposure." | 7.81 | Neutropenia secondary to exposure to levetiracetam. ( Boza, FM; Gumà I Padró, J; Peralta Muñoz, S; Taberner Bonastre, MT, 2015) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 7.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 7.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| " Approximately 30-40% of brain tumors patients who present with status epilepticus (SE) will not respond to typical therapy consisting of benzodiazepines and phenytoin (PHT), resulting in patients with refractory status epilepticus (RSE)." | 7.78 | Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. ( Doreswamy, M; Gingrich, KJ; Kolls, BJ; Swisher, CB; Vredenburgh, JJ, 2012) |
| "To correlate SV2A expression in surgically removed tumor and peritumoral tissue of glioma patients with epilepsy with the clinical response to levetiracetam in a prospective cohort." | 7.77 | Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. ( Aronica, E; de Groot, M; Heimans, JJ; Reijneveld, JC, 2011) |
| "Rare cases of levetiracetam-induced thrombocytopenia have been reported in the literature." | 7.76 | A case of levetiracetam-induced thrombocytopenia. ( Koubeissi, M; Nock, C; Oghlakian, R, 2010) |
| "To evaluate the efficacy and safety of levetiracetam in the management of epilepsy in patients with glioma." | 7.76 | Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. ( Buttolo, L; Cenzato, M; Padovani, A; Rosati, A; Stefini, R; Todeschini, A, 2010) |
| "The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy." | 7.75 | Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. ( Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Muti, P; Pace, A; Sperati, F, 2009) |
| "Levetiracetam (LEV) is a newer anticonvulsant with a favorable safety profile." | 6.77 | Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. ( Bähr, O; Franz, K; Hermisson, M; Körtvelyessy, P; Nussbaum, S; Rieger, J; Rona, S; Seifert, V; Steinbach, JP; Tatagiba, M; Weller, M, 2012) |
| "Epilepsy is a common clinical problem in patients with brain tumours, strongly affecting patients' quality of life." | 6.72 | Levetiracetam therapy in patients with brain tumour and epilepsy. ( Albani, F; Baruzzi, A; Carapella, CM; Dinapoli, L; Jandolo, B; Maschio, M; Occhipinti, E; Pace, A; Pompili, A; Zarabla, A, 2006) |
| "Nine patients had simple partial seizures, eight had complex partial seizures, and eight had secondary generalized seizures." | 5.46 | Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. ( Fabi, A; Giannarelli, D; Maialetti, A; Maschio, M; Vidiri, A; Villani, V; Zarabla, A, 2017) |
| "Initial seizure control with enteral levetiracetam was achieved, and when enteral and intravenous (i." | 5.43 | Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report. ( Chambers, J; Foreman, E; Mason, LD; Wells, GH, 2016) |
| "Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14." | 5.43 | Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016) |
| " Haematological toxicity is a limiting side effect of both, first line radio-chemotherapy with temozolomide (TMZ) and co-medication with antiepileptic drugs." | 5.42 | Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. ( Geroldinger, A; Gleiss, A; Grisold, W; Marosi, C; Moser, W; Oberndorfer, S; Sax, C; Sherif, C; Tinchon, A, 2015) |
| "The postoperative seizure control rates of levetiracetam and valproic acid were not statistically significantly different; however, levetiracetam may be superior to valproic acid in terms of its safety and durability after supratentorial tumor surgery." | 5.39 | Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review. ( Bae, SH; Han, JH; Kim, CY; Kim, T; Kim, YH; Lee, YJ; Yun, CH, 2013) |
| "To compare the incidence of seizures in patients receiving either prophylactic PHT or LEV perioperatively, 971 patients undergoing a craniotomy were analysed retrospectively during a 2-year period." | 5.38 | Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy. ( Brawanski, AT; Feigl, GC; Hansen, E; Kern, K; Lange, M; Schebesch, KM; Schlaier, J, 2012) |
| "We studied 23 patients with cancer and seizures treated with levetiracetam." | 5.35 | Levetiracetam for seizures in children with brain tumors and other cancers. ( Fisher, PG; Partap, S, 2009) |
| "We performed a case series analysis to evaluate the effects of levetiracetam (LEV) monotherapy on seizures, adverse events, cognitive functioning and quality of life (QoL) in patients with brain tumor-related epilepsy (BTRE)." | 5.15 | Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. ( Dinapoli, L; Fabi, A; Maschio, M; Muti, P; Pace, A; Sperati, F; Vidiri, A, 2011) |
| "Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures." | 5.14 | Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. ( Barbaro, N; Burt, M; Chakalian, L; Chang, E; Chang, S; Lamborn, KR; Lim, DA; McDermott, MW; Tarapore, P, 2009) |
| "To determine the safety and tolerability of IV and oral levetiracetam monotherapy for seizures in brain tumor patients following resection." | 4.86 | A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. ( Finch, CK; Michael, LM; Sills, AK; Usery, JB, 2010) |
| "Temozolomide (TMZ) is an alkylating agent used for treatment of brain neoplasms and levetiracetam (LEV) is a commonly used antiepileptic." | 3.85 | Acute liver injury induced by levetiracetam and temozolomide co-treatment. ( Abu Rmeileh, A; Benson, AA; Chen, S; Cohen, J; Daher, S; Khoury, T; Mizrahi, M; Yaari, S, 2017) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 3.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| "We report the case of an aborted awake craniotomy for a left frontotemporoinsular glioma due to ammonia encephalopathy on a patient taking Levetiracetam, valproic acid and clobazam." | 3.81 | Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy. ( Arroyo Pérez, R; Fernández-Candil, JL; León Jorba, A; Pacreu Terradas, S; Villalba Martínez, G; Vivanco-Hidalgo, RM, 2015) |
| "LEV may provide a survival benefit in patients with glioblastoma who receive temozolomide-based chemotherapy." | 3.81 | Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. ( Han, JH; Joo, JD; Kim, CY; Kim, IA; Kim, T; Kim, YH; Kim, YJ; Yun, CH, 2015) |
| "We report a case of neutropenia related to the use of levetiracetam at first exposure." | 3.81 | Neutropenia secondary to exposure to levetiracetam. ( Boza, FM; Gumà I Padró, J; Peralta Muñoz, S; Taberner Bonastre, MT, 2015) |
| "To examine the efficacy of valproic acid (VPA) given either with or without levetiracetam (LEV) on seizure control and on survival in patients with glioblastoma multiforme (GBM) treated with chemoradiation." | 3.79 | Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. ( Dielemans, JC; Kerkhof, M; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2013) |
| " Approximately 30-40% of brain tumors patients who present with status epilepticus (SE) will not respond to typical therapy consisting of benzodiazepines and phenytoin (PHT), resulting in patients with refractory status epilepticus (RSE)." | 3.78 | Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. ( Doreswamy, M; Gingrich, KJ; Kolls, BJ; Swisher, CB; Vredenburgh, JJ, 2012) |
| "An open pilot study to evaluate the effect of pregabalin (PGB) as add-on therapy on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy (BTRE)." | 3.78 | Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study. ( Carapella, CM; Dinapoli, L; Fabi, A; Maschio, M; Pace, A; Pompili, A; Sperati, F; Vidiri, A, 2012) |
| "To correlate SV2A expression in surgically removed tumor and peritumoral tissue of glioma patients with epilepsy with the clinical response to levetiracetam in a prospective cohort." | 3.77 | Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma. ( Aronica, E; de Groot, M; Heimans, JJ; Reijneveld, JC, 2011) |
| "Rare cases of levetiracetam-induced thrombocytopenia have been reported in the literature." | 3.76 | A case of levetiracetam-induced thrombocytopenia. ( Koubeissi, M; Nock, C; Oghlakian, R, 2010) |
| "To evaluate the efficacy and safety of levetiracetam in the management of epilepsy in patients with glioma." | 3.76 | Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. ( Buttolo, L; Cenzato, M; Padovani, A; Rosati, A; Stefini, R; Todeschini, A, 2010) |
| "The aim of this pilot study was to investigate the effects of levetiracetam monotherapy on seizure control, quality of life and neurocognitive performance in patients with brain tumor-related epilepsy." | 3.75 | Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study. ( Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Muti, P; Pace, A; Sperati, F, 2009) |
| "Phenytoin (PHT) is routinely used for seizure prophylaxis in patients with brain tumours during and after craniotomy, despite incomplete evidence." | 2.80 | Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Kuwabara, K; Matsumoto, M; Sakaida, T, 2015) |
| "In patients with brain tumors, the choice of antiepileptic medication is guided by tolerability and pharmacokinetic interactions." | 2.79 | Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. ( Jeckelmann, S; Novy, J; Rossetti, AO; Roth, P; Stupp, R; Weller, M, 2014) |
| "Levetiracetam (LEV) is a newer anticonvulsant with a favorable safety profile." | 2.77 | Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial. ( Bähr, O; Franz, K; Hermisson, M; Körtvelyessy, P; Nussbaum, S; Rieger, J; Rona, S; Seifert, V; Steinbach, JP; Tatagiba, M; Weller, M, 2012) |
| "Epilepsy is a common clinical problem in patients with brain tumours, strongly affecting patients' quality of life." | 2.72 | Levetiracetam therapy in patients with brain tumour and epilepsy. ( Albani, F; Baruzzi, A; Carapella, CM; Dinapoli, L; Jandolo, B; Maschio, M; Occhipinti, E; Pace, A; Pompili, A; Zarabla, A, 2006) |
| "Since surgery is believed to aggravate cerebral hypoxia and the consequent neurological dysfunction, patients undergoing surgery for brain tumours or ruptured cerebral aneurysms were studied." | 2.64 | Effect of piracetam on level of consciousness after neurosurgery. ( Bereen, FJ; Richardson, AE, 1977) |
| "SMART syndrome is a delayed complication of brain radiation characterized by neurologic symptoms including migraine-like headaches, seizures, and hemispheric impairment." | 2.55 | Stroke-like migraine attacks after radiation therapy syndrome: Case report and review of the literature. ( Altmeyer, WB; Moise, AM; Singh, AK; Tantiwongkosi, B, 2017) |
| "The tumor, a grade 3 anaplastic oligodendroglioma, was excised, and chemoradiotherapy was administered." | 2.55 | Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature. ( Abraham Koshy, A; Kumar A, A, 2017) |
| "Studies were included if they reported seizure frequency data pertaining to levetiracetam use in patients with brain tumors as either monotherapy or as an add on agent." | 2.53 | Levetiracetam for seizure prevention in brain tumor patients: a systematic review. ( Nasr, ZG; Paravattil, B; Wilby, KJ, 2016) |
| "The use of AEDs for purposes other than seizure prophylaxis and their selection based on non-PK properties present a potential paradigm shift in the field of neuro-oncology." | 2.53 | Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics. ( Gefroh-Grimes, HA; Gidal, BE, 2016) |
| "In most cases, either the seizure or the medications used to treat the seizure may contribute to cognitive and psychosocial difficulties of various degrees of severity." | 2.52 | Clinical Management of Seizures in Patients With Low-Grade Glioma. ( Blakeley, J; Piotrowski, AF, 2015) |
| "Patients with brain tumors remain at risk for infections from the perioperative period through many months after treatment, and steroids may mask signs of infection." | 2.52 | Medical management of patients with brain tumors. ( Pruitt, AA, 2015) |
| "Seizures are a common symptom of brain tumours." | 2.47 | Antiepileptic drugs for treating seizures in adults with brain tumours. ( Grant, R; Kerrigan, S, 2011) |
| "Epileptic seizures are a common clinical problem in children with brain tumors." | 2.46 | Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment? ( Attinà, G; Battaglia, D; Mastrangelo, S; Riccardi, R; Rizzo, D; Ruggiero, A, 2010) |
| "Therefore, the optimal seizure management by antiepileptic drugs (AEDs) in this patient category is essentially unsure." | 2.43 | Optimal seizure management in brain tumor patients. ( van Breemen, MS; Vecht, CJ, 2005) |
| "Nine patients had simple partial seizures, eight had complex partial seizures, and eight had secondary generalized seizures." | 1.46 | Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. ( Fabi, A; Giannarelli, D; Maialetti, A; Maschio, M; Vidiri, A; Villani, V; Zarabla, A, 2017) |
| " Psychiatric symptoms occurring after initiation of AED therapy were considered as treatment emergent psychiatric adverse events (TE-PAEs) if they fulfilled the following conditions: (1) onset within 4 weeks after the beginning of AED therapy; (2) disappearance on drug discontinuation; (3) absence of any other identified possible concurrent cause." | 1.46 | Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study. ( Belcastro, V; Bellocchi, S; Casiraghi, P; Gorgone, G; Mula, M; Pisani, F; Pisani, LR, 2017) |
| " Evaluating non-neurobehavioural adverse events of AEDs, no significant differences were found among AEDs, although patients treated with old AEDs had a higher prevalence of adverse events than those treated with new AEDs." | 1.46 | Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study. ( Bedetti, C; Calabresi, P; Costa, C; Di Bonaventura, C; Dispenza, S; Eusebi, P; Maschio, M; Nardi Cesarini, E; Romoli, M; Siliquini, S, 2017) |
| "Patients with grade IV astrocytoma or glioblastoma multiforme (GBM) have a median survival of <12 months, increased to 14." | 1.43 | Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam. ( Ajit, NE; Burton, GV; El-Osta, H; Peddi, P, 2016) |
| "Initial seizure control with enteral levetiracetam was achieved, and when enteral and intravenous (i." | 1.43 | Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report. ( Chambers, J; Foreman, E; Mason, LD; Wells, GH, 2016) |
| " Haematological toxicity is a limiting side effect of both, first line radio-chemotherapy with temozolomide (TMZ) and co-medication with antiepileptic drugs." | 1.42 | Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. ( Geroldinger, A; Gleiss, A; Grisold, W; Marosi, C; Moser, W; Oberndorfer, S; Sax, C; Sherif, C; Tinchon, A, 2015) |
| "Levetiracetam was very well tolerated." | 1.42 | Epilepsy in patients with gliomas: incidence and control of seizures. ( Hasegawa, Y; Iuchi, T; Kawasaki, K; Sakaida, T, 2015) |
| "The postoperative seizure control rates of levetiracetam and valproic acid were not statistically significantly different; however, levetiracetam may be superior to valproic acid in terms of its safety and durability after supratentorial tumor surgery." | 1.39 | Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review. ( Bae, SH; Han, JH; Kim, CY; Kim, T; Kim, YH; Lee, YJ; Yun, CH, 2013) |
| "53." | 1.39 | Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs. ( Buniak, L; Henry, JC; Mohile, N; Wang, H; Wychowski, T, 2013) |
| "To compare the incidence of seizures in patients receiving either prophylactic PHT or LEV perioperatively, 971 patients undergoing a craniotomy were analysed retrospectively during a 2-year period." | 1.38 | Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy. ( Brawanski, AT; Feigl, GC; Hansen, E; Kern, K; Lange, M; Schebesch, KM; Schlaier, J, 2012) |
| "Breakthrough seizure activity has been reported with conversion from brand name to generic anticonvulsants." | 1.36 | Seizure risk in brain tumor patients with conversion to generic levetiracetam. ( Armstrong, TS; Choi, S; Gilbert, MR; Walker, J, 2010) |
| "Although seizures in brain tumor patients are common, the knowledge on optimal anti-seizure therapy in this patient group is limited." | 1.35 | Efficacy of anti-epileptic drugs in patients with gliomas and seizures. ( Rijsman, RM; Taphoorn, MJ; van Breemen, MS; Vecht, CJ; Walchenbach, R; Zwinkels, H, 2009) |
| "Almost all (94%) had supratentorial tumors, of which 78% were glial tumors." | 1.35 | The use of antiepileptic drugs in pediatric brain tumor patients. ( Kan, L; Levy, AS; Maytal, J; Shinnar, S; Sogawa, Y, 2009) |
| "We studied 23 patients with cancer and seizures treated with levetiracetam." | 1.35 | Levetiracetam for seizures in children with brain tumors and other cancers. ( Fisher, PG; Partap, S, 2009) |
| "Levetiracetam (LEV) is a 2nd generation non-enzyme inducing AED with a novel mechanism of action, binding to neuronal synaptic vesicle protein SV2A, that has been previously shown to reduce seizure activity in patients with primary brain tumors." | 1.34 | Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. ( Dalton, J; Goldlust, S; Newton, HB; Pearl, D, 2007) |
| "Older patients and patients with brain tumors or strokes were preferentially treated with LEV for prevention and/or management of seizures (all P < or = 0." | 1.34 | Levetiracetam use in critically ill patients. ( Meckler, JM; Privitera, MD; Shutter, LA; Szaflarski, JP; Szaflarski, M; Yates, SL, 2007) |
| "Seizures are a common complication of primary (PBT) and metastatic (MBT) brain tumors, affecting approximately 50% of all patients during the course of their illness." | 1.33 | Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. ( Goldlust, SA; Newton, HB; Pearl, D, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.41) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 16 (23.53) | 29.6817 |
| 2010's | 48 (70.59) | 24.3611 |
| 2020's | 1 (1.47) | 2.80 |
| Authors | Studies |
|---|---|
| Konrath, E | 1 |
| Marhold, F | 1 |
| Kindler, W | 1 |
| Scheichel, F | 1 |
| Popadic, B | 1 |
| Blauensteiner, K | 1 |
| Calabek, B | 1 |
| Freydl, E | 1 |
| Weber, M | 1 |
| Ristl, R | 1 |
| Hainz, K | 1 |
| Sherif, C | 2 |
| Oberndorfer, S | 2 |
| Belcastro, V | 1 |
| Pisani, LR | 1 |
| Bellocchi, S | 1 |
| Casiraghi, P | 1 |
| Gorgone, G | 1 |
| Mula, M | 1 |
| Pisani, F | 1 |
| Tountopoulou, M | 1 |
| Weschke, B | 1 |
| Kaindl, AM | 1 |
| Maschio, M | 7 |
| Zarabla, A | 2 |
| Maialetti, A | 1 |
| Fabi, A | 4 |
| Vidiri, A | 3 |
| Villani, V | 1 |
| Giannarelli, D | 1 |
| Singh, AK | 1 |
| Tantiwongkosi, B | 1 |
| Moise, AM | 1 |
| Altmeyer, WB | 1 |
| Bedetti, C | 1 |
| Romoli, M | 1 |
| Di Bonaventura, C | 1 |
| Nardi Cesarini, E | 1 |
| Eusebi, P | 1 |
| Siliquini, S | 1 |
| Dispenza, S | 1 |
| Calabresi, P | 1 |
| Costa, C | 1 |
| Kumar A, A | 1 |
| Abraham Koshy, A | 1 |
| Feyissa, AM | 1 |
| López-Saca, JM | 1 |
| Vaquero, J | 1 |
| Larumbe, A | 1 |
| Urdíroz, J | 1 |
| Centeno, C | 1 |
| Kerkhof, M | 1 |
| Dielemans, JC | 1 |
| van Breemen, MS | 3 |
| Zwinkels, H | 2 |
| Walchenbach, R | 2 |
| Taphoorn, MJ | 2 |
| Vecht, CJ | 3 |
| Weller, M | 4 |
| Lee, YJ | 1 |
| Kim, T | 2 |
| Bae, SH | 1 |
| Kim, YH | 2 |
| Han, JH | 2 |
| Yun, CH | 2 |
| Kim, CY | 2 |
| Wychowski, T | 1 |
| Wang, H | 1 |
| Buniak, L | 1 |
| Henry, JC | 1 |
| Mohile, N | 1 |
| Rossetti, AO | 2 |
| Jeckelmann, S | 1 |
| Novy, J | 2 |
| Roth, P | 2 |
| Stupp, R | 2 |
| Iuchi, T | 2 |
| Hasegawa, Y | 2 |
| Kawasaki, K | 2 |
| Sakaida, T | 2 |
| Tinchon, A | 1 |
| Marosi, C | 1 |
| Gleiss, A | 1 |
| Geroldinger, A | 1 |
| Sax, C | 1 |
| Moser, W | 1 |
| Grisold, W | 1 |
| Villalba Martínez, G | 1 |
| Fernández-Candil, JL | 1 |
| Vivanco-Hidalgo, RM | 1 |
| Pacreu Terradas, S | 1 |
| León Jorba, A | 1 |
| Arroyo Pérez, R | 1 |
| Kuwabara, K | 1 |
| Matsumoto, M | 1 |
| Simpao, AF | 1 |
| Janik, LS | 1 |
| Hsu, G | 1 |
| Schwartz, AJ | 1 |
| Heuer, GG | 1 |
| Warrington, AP | 1 |
| Rehman, MA | 1 |
| Pruitt, AA | 1 |
| Joo, JD | 1 |
| Kim, YJ | 1 |
| Kim, IA | 1 |
| Gefroh-Grimes, HA | 1 |
| Gidal, BE | 1 |
| Taberner Bonastre, MT | 1 |
| Peralta Muñoz, S | 1 |
| Boza, FM | 1 |
| Gumà I Padró, J | 1 |
| Piotrowski, AF | 1 |
| Blakeley, J | 1 |
| Hatanpaa, KJ | 1 |
| Fuda, F | 1 |
| Koduru, P | 1 |
| Young, K | 1 |
| Lega, B | 1 |
| Chen, W | 1 |
| Wells, GH | 1 |
| Mason, LD | 1 |
| Foreman, E | 1 |
| Chambers, J | 1 |
| Happold, C | 1 |
| Gorlia, T | 1 |
| Chinot, O | 1 |
| Gilbert, MR | 2 |
| Nabors, LB | 1 |
| Wick, W | 1 |
| Pugh, SL | 1 |
| Hegi, M | 1 |
| Cloughesy, T | 1 |
| Reardon, DA | 1 |
| Perry, JR | 1 |
| Mehta, MP | 1 |
| Sonis, J | 1 |
| Borczuk, P | 1 |
| Ptak, T | 1 |
| Miller, ES | 1 |
| Nasr, ZG | 1 |
| Paravattil, B | 1 |
| Wilby, KJ | 1 |
| Habets, JGV | 1 |
| Leentjens, AFG | 1 |
| Schijns, OEMG | 1 |
| Peddi, P | 1 |
| Ajit, NE | 1 |
| Burton, GV | 1 |
| El-Osta, H | 1 |
| Khoury, T | 1 |
| Chen, S | 1 |
| Abu Rmeileh, A | 1 |
| Daher, S | 1 |
| Yaari, S | 1 |
| Benson, AA | 1 |
| Cohen, J | 1 |
| Mizrahi, M | 1 |
| Lee, JW | 2 |
| Bromfield, E | 1 |
| Kesari, S | 3 |
| Partap, S | 1 |
| Fisher, PG | 1 |
| Bromfield, EB | 1 |
| Shershever, AS | 1 |
| Bentsion, DL | 1 |
| Lavrova, SA | 1 |
| Sorokova, EV | 1 |
| Carota, A | 1 |
| Lim, DA | 1 |
| Tarapore, P | 1 |
| Chang, E | 1 |
| Burt, M | 1 |
| Chakalian, L | 1 |
| Barbaro, N | 1 |
| Chang, S | 1 |
| Lamborn, KR | 1 |
| McDermott, MW | 1 |
| Dinapoli, L | 5 |
| Jandolo, B | 3 |
| Pace, A | 4 |
| Sperati, F | 3 |
| Muti, P | 2 |
| Rijsman, RM | 1 |
| Sogawa, Y | 1 |
| Kan, L | 1 |
| Levy, AS | 1 |
| Maytal, J | 1 |
| Shinnar, S | 1 |
| Ruggiero, A | 1 |
| Rizzo, D | 1 |
| Mastrangelo, S | 1 |
| Battaglia, D | 1 |
| Attinà, G | 1 |
| Riccardi, R | 1 |
| Eggers, C | 1 |
| Burghaus, L | 1 |
| Fink, GR | 1 |
| Dohmen, C | 1 |
| Armstrong, TS | 1 |
| Choi, S | 1 |
| Walker, J | 1 |
| Usery, JB | 1 |
| Michael, LM | 1 |
| Sills, AK | 1 |
| Finch, CK | 1 |
| Rosati, A | 1 |
| Buttolo, L | 1 |
| Stefini, R | 1 |
| Todeschini, A | 1 |
| Cenzato, M | 1 |
| Padovani, A | 1 |
| Oghlakian, R | 1 |
| Nock, C | 1 |
| Koubeissi, M | 1 |
| Engh, JA | 1 |
| de Groot, M | 2 |
| Aronica, E | 1 |
| Heimans, JJ | 2 |
| Reijneveld, JC | 2 |
| Kerrigan, S | 1 |
| Grant, R | 1 |
| Swisher, CB | 1 |
| Doreswamy, M | 1 |
| Gingrich, KJ | 1 |
| Vredenburgh, JJ | 1 |
| Kolls, BJ | 1 |
| Bähr, O | 1 |
| Hermisson, M | 1 |
| Rona, S | 1 |
| Rieger, J | 1 |
| Nussbaum, S | 1 |
| Körtvelyessy, P | 1 |
| Franz, K | 1 |
| Tatagiba, M | 1 |
| Seifert, V | 1 |
| Steinbach, JP | 1 |
| Mahta, A | 1 |
| Kim, RY | 1 |
| Kern, K | 1 |
| Schebesch, KM | 1 |
| Schlaier, J | 1 |
| Hansen, E | 1 |
| Feigl, GC | 1 |
| Brawanski, AT | 1 |
| Lange, M | 1 |
| Fisch, L | 1 |
| Mégevand, P | 1 |
| Badoud, S | 1 |
| Badoud, A | 1 |
| Seeck, M | 1 |
| Burkhard, PR | 1 |
| Douw, L | 1 |
| Sizoo, EM | 1 |
| Bosma, I | 1 |
| Froklage, FE | 1 |
| Postma, TJ | 1 |
| Klein, M | 1 |
| Pompili, A | 2 |
| Carapella, CM | 2 |
| Wagner, GL | 1 |
| Wilms, EB | 1 |
| Van Donselaar, CA | 1 |
| Vecht, ChJ | 1 |
| Newton, HB | 2 |
| Goldlust, SA | 1 |
| Pearl, D | 2 |
| Albani, F | 1 |
| Baruzzi, A | 1 |
| Occhipinti, E | 1 |
| Dalton, J | 1 |
| Goldlust, S | 1 |
| Szaflarski, JP | 1 |
| Meckler, JM | 1 |
| Szaflarski, M | 1 |
| Shutter, LA | 1 |
| Privitera, MD | 1 |
| Yates, SL | 1 |
| von Metzler, A | 2 |
| Nitsch, C | 2 |
| Richardson, AE | 1 |
| Bereen, FJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients[NCT02815410] | Phase 2 | 73 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study)[NCT00571155] | Phase 4 | 30 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for piracetam and Brain Neoplasms
| Article | Year |
|---|---|
Stroke-like migraine attacks after radiation therapy syndrome: Case report and review of the literature.
Topics: Adult; Brain Neoplasms; Female; Humans; Levetiracetam; Magnetic Resonance Imaging; Migraine Disorder | 2017 |
Regression of Recurrent High-Grade Glioma with Temozolomide, Dexamethasone, and Levetiracetam: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Corpus Ca | 2017 |
Medical management of patients with brain tumors.
Topics: Angiogenesis Inhibitors; Anticonvulsants; Brain Edema; Brain Neoplasms; Cognition Disorders; Dopamin | 2015 |
Antiepileptic drugs in patients with malignant brain tumor: beyond seizures and pharmacokinetics.
Topics: Animals; Anticonvulsants; Brain Neoplasms; Carbamazepine; Humans; Levetiracetam; Piracetam; Seizures | 2016 |
Clinical Management of Seizures in Patients With Low-Grade Glioma.
Topics: Anticonvulsants; Brain Neoplasms; Glioma; Humans; Lamotrigine; Levetiracetam; Piracetam; Seizures; T | 2015 |
Levetiracetam for seizure prevention in brain tumor patients: a systematic review.
Topics: Anticonvulsants; Brain Neoplasms; Humans; Levetiracetam; Observational Studies as Topic; Piracetam; | 2016 |
Interactions between antiepileptic and chemotherapeutic drugs in children with brain tumors: is it time to change treatment?
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Child; Child, Preschool; Drug Interactions; | 2010 |
A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Dru | 2010 |
Antiepileptic drugs for treating seizures in adults with brain tumours.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Drug Substitution; Humans; Levetiracetam; Phenytoin; Pirace | 2011 |
Optimal seizure management in brain tumor patients.
Topics: Amines; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Cyclohexanecarboxylic Acids; Drug I | 2005 |
7 trials available for piracetam and Brain Neoplasms
| Article | Year |
|---|---|
Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Follow-Up Studies; gamma-Aminobutyric Acid; Huma | 2014 |
Levetiracetam versus phenytoin for seizure prophylaxis during and early after craniotomy for brain tumours: a phase II prospective, randomised study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Cohort Studies; Cranio | 2015 |
Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Craniotomy; Female; Glioma; Humans | 2009 |
Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Follow-Up Studies; Humans; Levetira | 2011 |
Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Brain Neoplasms; Chemotherapy, Adjuvant; Electro | 2012 |
Levetiracetam therapy in patients with brain tumour and epilepsy.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Female; Humans; | 2006 |
Effect of piracetam on level of consciousness after neurosurgery.
Topics: Brain Neoplasms; Cerebral Cortex; Consciousness; Humans; Hypoxia, Brain; Intracranial Aneurysm; Pira | 1977 |
51 other studies available for piracetam and Brain Neoplasms
| Article | Year |
|---|---|
Perioperative levetiracetam for seizure prophylaxis in seizure-naive brain tumor patients with focus on neurocognitive functioning.
Topics: Anticonvulsants; Brain Neoplasms; Humans; Levetiracetam; Piracetam; Prospective Studies; Quality of | 2022 |
Brain tumor location influences the onset of acute psychiatric adverse events of levetiracetam therapy: an observational study.
Topics: Aged; Anticonvulsants; Brain Neoplasms; Cohort Studies; Electroencephalography; Epilepsy; Female; Hu | 2017 |
Lacosamide Lowers Valproate and Levetiracetam Levels.
Topics: Acetamides; Adolescent; Anticonvulsants; Brain Neoplasms; Drug Interactions; Epilepsies, Partial; Hu | 2017 |
Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
Topics: Acetamides; Adult; Affect; Aged; Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilep | 2017 |
Neuropsychiatric adverse events of antiepileptic drugs in brain tumour-related epilepsy: an Italian multicentre prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Epilepsy; Female; Humans; Italy; L | 2017 |
Antiepileptic drug-related neuropsychiatric adverse events in brain tumor-related epilepsy: levetiracetam front and center.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsy; Humans; Levetiracetam; Piracetam | 2017 |
Repeated use of subcutaneous levetiracetam in a palliative care patient.
Topics: Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Epilepsy; Female; Humans; | 2013 |
Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; | 2013 |
Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma?
Topics: Anticonvulsants; Brain Neoplasms; Female; Glioblastoma; Humans; Levetiracetam; Male; Neoplasm Recurr | 2013 |
Levetiracetam compared with valproic acid for the prevention of postoperative seizures after supratentorial tumor surgery: a retrospective chart review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Child; Child, Preschoo | 2013 |
Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Male; Midd | 2013 |
Epilepsy in patients with gliomas: incidence and control of seizures.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Female; Glioma; Humans; Inci | 2015 |
Haematological toxicity of Valproic acid compared to Levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study.
Topics: Adult; Aged; Anticonvulsants; Blood Cell Count; Blood Cells; Brain Neoplasms; Chemoradiotherapy; Fem | 2015 |
Ammonia encephalopathy and awake craniotomy for brain language mapping: cause of failed awake craniotomy.
Topics: Anesthesia, General; Anesthesia, Local; Anticonvulsants; Aphasia; Benzodiazepines; Brain Diseases; B | 2015 |
Transient and reproducible loss of motor-evoked potential signals after intravenous levetiracetam in a child undergoing craniotomy for resection of astrocytoma.
Topics: Anticonvulsants; Astrocytoma; Brain Neoplasms; Child; Craniotomy; Evoked Potentials, Motor; Evoked P | 2015 |
Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Ne | 2015 |
Neutropenia secondary to exposure to levetiracetam.
Topics: Adenocarcinoma; Anticonvulsants; Brain Neoplasms; Craniotomy; Drug Administration Schedule; Humans; | 2015 |
Lymphomatosis Cerebri: A Diagnostic Challenge.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; DNA-Binding Proteins; Female; Frontal Lobe; Humans; Im | 2015 |
Continuous subcutaneous levetiracetam in the management of seizures at the end of life: a case report.
Topics: Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Carcinoma, Squamous Cell; Head and Neck Neoplas | 2016 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2016 |
Seizure and Fever.
Topics: Acyclovir; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antiviral Agents; Brain Neoplasms; Ceftri | 2016 |
Serious and reversible levetiracetam-induced psychiatric symptoms after resection of frontal low-grade glioma: two case histories.
Topics: Anticonvulsants; Brain Neoplasms; Craniotomy; Epilepsy; Frontal Lobe; Humans; Levetiracetam; Magneti | 2017 |
Regression of a glioblastoma multiforme: spontaneous versus a potential antineoplastic effect of dexamethasone and levetiracetam.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cognition Disorders; D | 2016 |
Acute liver injury induced by levetiracetam and temozolomide co-treatment.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Studi | 2017 |
Emesis responsive to levetiracetam.
Topics: Aged; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Papilloma, Choroid Plexus; Pi | 2008 |
Levetiracetam for seizures in children with brain tumors and other cancers.
Topics: Adolescent; Anticonvulsants; Brain Neoplasms; Child; Drug Evaluation; Female; Humans; Levetiracetam; | 2009 |
Antiemetic properties of the antiepileptic drug levetiracetam.
Topics: Age Factors; Anticonvulsants; Antiemetics; Antineoplastic Agents; Brain Neoplasms; Glioblastoma; Hum | 2008 |
[Use of keppra during the radiotherapy in patients with brain tumors and epileptic seizures after surgical treatment].
Topics: Administration, Oral; Adolescent; Adult; Anticonvulsants; Brain Neoplasms; Child; Dose-Response Rela | 2008 |
Symptomatic complex partial status epilepticus manifesting as utilization behavior of a mobile phone.
Topics: Anticonvulsants; Benzodiazepines; Brain Neoplasms; Cell Phone; Clobazam; Electroencephalography; Epi | 2009 |
Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study.
Topics: Activities of Daily Living; Adult; Aged; Anticonvulsants; Blood Cell Count; Brain Neoplasms; Combine | 2009 |
Efficacy of anti-epileptic drugs in patients with gliomas and seizures.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Carbamazepine; Drug Therapy, Combination; Female; Follow-Up | 2009 |
The use of antiepileptic drugs in pediatric brain tumor patients.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Child; Drug Interactions; Fo | 2009 |
Epilepsia partialis continua responsive to intravenous levetiracetam.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsies, Partial; Female; Humans; Injections, Intravenous; Leve | 2009 |
Seizure risk in brain tumor patients with conversion to generic levetiracetam.
Topics: Adult; Anticonvulsants; Brain Neoplasms; Drugs, Generic; Female; Humans; Levetiracetam; Male; Middle | 2010 |
Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Dose-Response Relationship, Drug; Epilepsy; Female; G | 2010 |
In reference to Usery JB et al. (J Neuro-oncol. 2010 Feb 10).
Topics: Brain Neoplasms; Humans; Levetiracetam; Nootropic Agents; Piracetam; Prospective Studies | 2010 |
A case of levetiracetam-induced thrombocytopenia.
Topics: Anticonvulsants; Brain Neoplasms; Epilepsies, Partial; Female; Frontal Lobe; Glioblastoma; Humans; L | 2010 |
Anti-convulsants and gene expression in malignant gliomas.
Topics: Brain Neoplasms; Convulsants; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplast | 2010 |
Synaptic vesicle protein 2A predicts response to levetiracetam in patients with glioma.
Topics: Adult; Aged; Blotting, Western; Brain Neoplasms; Cohort Studies; Epilepsy; False Positive Reactions; | 2011 |
Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors.
Topics: Acute Disease; Aged; Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Female; gamma-Amin | 2012 |
Levetiracetam-induced interstitial nephritis in a patient with glioma.
Topics: Acute Kidney Injury; Anticonvulsants; Astrocytoma; Brain Neoplasms; Humans; Levetiracetam; Male; Mid | 2012 |
Levetiracetam compared to phenytoin for the prevention of postoperative seizures after craniotomy for intracranial tumours in patients without epilepsy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Child; Contraindications; Craniotomy; F | 2012 |
Pilomotor seizure: when paroxysmal gooseflesh heralds brain tumor.
Topics: Aged; Amygdala; Anticonvulsants; Astrocytoma; Brain Neoplasms; Electroencephalography; Hippocampus; | 2012 |
Levetiracetam improves verbal memory in high-grade glioma patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Brain Neoplasms; Cognition Disorders; Female; Glioma; Huma | 2013 |
Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.
Topics: Adult; Aged; Anticonvulsants; Anxiety; Benzodiazepines; Brain Neoplasms; Carbamazepine; Clobazam; Dr | 2012 |
Levetiracetam: preliminary experience in patients with primary brain tumours.
Topics: Brain Neoplasms; Follow-Up Studies; Glioma; Humans; Levetiracetam; Piracetam; Prospective Studies; S | 2003 |
Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Mal | 2006 |
Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors.
Topics: Adult; Aged; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Male; Middle Aged; Pir | 2007 |
Levetiracetam use in critically ill patients.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Diseases; Brain Ne | 2007 |
[Effects of 3-methylcholanthrene and 3-methylcholanthrene plus piracetam on the gamma-amino-butyric acid (GABA) content of several cerebral regions (author's transl)].
Topics: Aminooxyacetic Acid; Animals; Brain Chemistry; Brain Neoplasms; gamma-Aminobutyric Acid; Methylchola | 1981 |
Monoamine content in rat brain during carcinogenesis and the influence of the CNS drugs piracetam and imipramine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Brain Neoplasms; Caudate Nucleus; Female; | 1985 |